Current Approaches to Optimize Schizophrenia Management: Fundamentals for Managed Markets

Slide Lecture with Audio

Sponsored by North American Center for Continuing Medical Education, LLC

FACULTY

Main Presenter/Q&A Cohost

Christoph U. Correll, MD
Medical Director, Recognition and Prevention (RAP) Program
Director, Adverse Events Unit
Advanced Center for Intervention and Services Research
The Zucker Hillside Hospital
North Shore – Long Island Jewish Health System
Associate Professor of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Bronx, New York

Co-presenter/Q&A Cohost

William J. Cardarelli, PharmD
Director of Pharmacy
Atrius Health
Harvard Vanguard Medical Associates
Watertown, Massachusetts

Target Audience

This activity is designed for managed markets physicians and pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

Outline the impact of schizophrenia and comorbidities on patient quality of life and healthcare resource use
Describe the role of integration of care in optimizing outcomes in schizophrenia patients
Identify opportunities for improved patient adherence with current and newer antipsychotics
Relate appropriate access to and use of evidence-based schizophrenia management to improved patient quality of life and reduced healthcare resource use

Activity Overview

This on-demand slide lecture with audio is available with HTML slides and the presentation transcript.
To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: February 12, 2010

Expiration Date: February 12, 2011

Estimated time to complete: 1 hour

For questions regarding this activity, please call 609-371-1137.

This educational activity is a knowledge-based activity.

Hardware/Software Requirements

All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

CME Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CPE Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-000-10-001-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or by e-mail at jsavage@naccme.com. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Ira Glick, MD, Professor of Psychiatry, Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Stanford, California

Planning Committee

The Planning Committee comprises Christoph U. Corrrell, MD, William J. Cardarelli, PharmD, Ira Glick, MD; and Randy Robbin, Rosemary Hodgson, Emilie McCardell, John Savage, and William Kormos, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are indentified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Correll: Scientific Consultant/Advisor/Promotional Speakers’ Bureau—Actelion Pharmaceuticals Ltd, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Cephalon, Eli Lilly & Company, GSK, Hoffma-LaRoche, Janssen Pharmaceuticals, Inc, Lundbeck, Inc, MedAvante Inc, Medicure Inc, Pfizer Inc, Otsuka Pharmaceutical Company, Ltd, Schering-Plough, Supernus Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Vanda Pharmaceuticals; Grant/Research Support—National Institute of Mental Health, Feinstein Institute for Medical Research, National Alliance for Research on Schizophrenia and Depression, American Academy of Child and Adolescent Psychiatry

Dr. Cardarelli has disclosed no relevant financial relationships with any commercial interests.

Dr. Glick: Grant/Research Support—Lundbeck Inc, National Institute of Mental Health, Otsuka Pharmaceutical Company, Ltd, Pfizer Inc; Scientific Consultant—Janssen Pharmaceuticals, Inc; Promotional Speakers’ Bureau—AstraZeneca Pharmaceuticals

Mr. Robbin, Ms. Hodgson, Ms. McCardell, Mr. Savage, and Mr. Kormos have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved use(s) of drugs and/or devices will be discussed.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate reporting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright ©2010 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing medical education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support

Supported by an educational grant from Bristol-Myers Squibb Company.